GlycoVaxyn

Switzerland
Schlieren, Zurich, Switzerland, 8952

Company profile

GlycoVaxyn company profile

GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections.

Business identity

Phone number
+41447338585
Operating status
Closed
Company type
For Profit
Employee range
11-50 employees
Founded
2004-01-01, Year

Headquarters

Postal code
8952
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
4
Total equity funding
$30.9M
Last funding
Grant / $3.4M / 2010-05-04
Last equity funding
Series B / $21.4M
Investors
3
Lead investors
3
Articles
3
Closed on
2015-02-11
Exited on
2015-02-11

Founders and investors

Lead investors

Edmond de Rothschild Private EquityIndex VenturesSofinnova Partners

Investors

Edmond de Rothschild Private EquityIndex VenturesSofinnova Partners